SecBot SecBot
8-K ·Filed May 6, 2026

LFCR

LIFECORE BIOMEDICAL, INC. \DE\
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001005286-26-000018
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The 34% revenue decline and margin compression confirm the structural headwinds flagged in prior guidance (customer loss, inventory build, delayed launch). The reaffirmed guidance implies a sharp H2 ramp that carries execution risk. Monitor Q2 results for any guidance revision and watch for preferred stock redemption demands starting June 29, 2026, which could pressure liquidity.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.96
T+0 close · May 6, 2026 · via day close
Latest settled
−10.89%
T+60 · $4.42
Vs SPY
−12.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $4.96entry
  2. T+1 · 6mo ago −3.83%α −3.50% · $4.77
  3. T+5 · 6mo ago −8.06%α −9.20% · $4.56
  4. T+20 · 6mo ago +14.31%α +11.53% · $5.67
  5. T+60 · 4mo ago −10.89%α −12.95% · $4.42

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net loss of $15.0M ($0.43/share) vs a $14.8M loss in the prior year. Adjusted EBITDA fell to $1.0M from $5.7M. The company reaffirmed its full-year 2026 guidance of $120-125M revenue and $20.5-25M Adjusted EBITDA, citing cost reductions and new commercial program wins, but the sharp revenue drop and widening losses signal ongoing operational challenges.

Key Financial Metrics

EPS
−$0.43
est −$0.24 · -79.2%
Revenue
$23.2M
est $26.0M · -10.8% · -34.0% YoY
Rating
strong miss
Guidance
$120M-$125M
maintained
Free Cash Flow
$3.6M
Gross Margin
19.2%

Key Facts

  • Q1 2026 revenue of $23.2M, down 34% YoY from $35.2M
  • Net loss of $15.0M ($0.43/share) vs $14.8M ($0.42/share) in prior year
  • Adjusted EBITDA fell to $1.0M from $5.7M YoY
  • Gross margin contracted to 19.2% from 28.0% YoY
  • Reaffirmed FY2026 guidance: revenue $120-125M, Adj. EBITDA $20.5-25M
  • Signed three new commercial site transfer programs in Q1
  • Cash from operations was $4.7M; free cash flow was $3.6M
  • Ended Q1 with $38.1M liquidity ($20.8M cash + $17.3M revolver availability)

Financial Impact

Revenue decline of $12.0M (34% YoY); net loss widened by $0.2M; Adjusted EBITDA down $4.7M

revenuenet incomeadjusted EBITDAgross margin

Risk Factors

  • Revenue concentration risk with largest customer's demand shift to 2027
  • Series A preferred stock redemption of $50.2M becomes demandable June 29, 2026
  • Debt of $147.8M (including related party) with PIK interest escalating
  • Negative stockholders' equity of $28.4M as of March 31, 2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001005286-26-000018
Exhibit: ex992_lfcrpresentation.htm0001005286-26-000018
Document: lndc-20260506.htm0001005286-26-000018
Document: 0001005286-26-000018-index-headers.html0001005286-26-000018
Document: 0001005286-26-000018-index.html0001005286-26-000018
Document: 0001005286-26-000018.txt0001005286-26-000018
8-K Data (Synthetic)0001005286-26-000018

Track record

20 reports on LFCR

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026